Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Kaiser

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Archives of Gynecology and Obstetrics|January 6, 2026
Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)Jacek P Grabowski, Julia Welz, Sabine Heublein, et al.
Gynecologic Oncology|October 18, 2025
Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center studyTabea Maurer, Matthias H Belau, Birgit-Christiane Zyriax, et al.
JAMA Oncology|June 25, 2026
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP InhibitorsLucy Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Archives of Gynecology and Obstetrics|January 6, 2026
Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)Jacek P Grabowski, Julia Welz, Sabine Heublein, et al.
Gynecologic Oncology|October 18, 2025
Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center studyTabea Maurer, Matthias H Belau, Birgit-Christiane Zyriax, et al.
JAMA Oncology|June 25, 2026
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP InhibitorsLucy Haggstrom, Yeh Chen Lee, Maria-Pilar Barretina-Ginesta, et al.
Pageof 2